Mersana Therapeutics Inc (NASDAQ:MRSN)’s Trend Up, Especially After Decreased Shorts

June 2, 2018 - By Peter Erickson

The stock of Mersana Therapeutics Inc (NASDAQ:MRSN) registered a decrease of 4.03% in short interest. MRSN’s total short interest was 1.84 million shares in June as published by FINRA. Its down 4.03% from 1.91 million shares, reported previously. With 60,900 shares average volume, it will take short sellers 30 days to cover their MRSN’s short positions. The short interest to Mersana Therapeutics Inc’s float is 18.69%.

The stock decreased 1.10% or $0.23 during the last trading session, reaching $20.7. About 155,804 shares traded or 23.06% up from the average. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since June 2, 2017 and is . It has underperformed by 12.57% the S&P500.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $474.07 million. The firm develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” on May 25, 2018, also Nasdaq.com with their article: “Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference” published on May 24, 2018, Globenewswire.com published: “Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates” on May 07, 2018. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: Streetinsider.com and their article: “Mersana Therapeutics (MRSN) to Present Interim Phase 1 Data on XMT-1522 at ASCO” published on May 22, 2018 as well as Benzinga.com‘s news article titled: “Baird: Mersana Is A Buy On Differentiated Platform For Cancer Indications” with publication date: May 08, 2018.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: